Brief: Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics

06/12/2023 12:09

Dec 6 (Reuters) - Coya Therapeutics Inc  COYA.O :
    * COYA THERAPEUTICS, INC. AND DR. REDDY’S LABORATORIES ENTER
INTO
AN EXCLUSIVE COLLABORATION FOR DEVELOPMENT AND COMMERCIALIZATION
OF COYA 302, AN INVESTIGATIONAL COMBINATION THERAPY FOR
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    * COYA THERAPEUTICS: DR. REDDY'S TO OBTAIN COMMERCIALIZATION
RIGHTS FOR COYA 302 IN US, CANADA, EUROPEAN UNION AND UNITED
KINGDOM, FOR PATIENTS WITH ALS
    * COYA THERAPEUTICS: CO RESPONSIBLE FOR DEVELOPMENT,
INCLUDING
CONDUCT OF PHASE 2 CLINICAL TRIAL AND FOR OBTAINING REGULATORY
APPROVAL IN US FOR DRUG
    * COYA THERAPEUTICS INC: DR. REDDY'S WILL MAKE A USD 7.5
MILLION
UPFRONT PAYMENT TO COYA
    * COYA THERAPEUTICS INC: ANTICIPATES THAT IND FILING WILL BE
MADE
IN FIRST HALF OF 2024
    * COYA THERAPEUTICS INC: DR. REDDY'S WILL PAY COYA AN
ADDITIONAL
USD 4.2 MILLION UNDER SOME CONDITIONS
    * COYA THERAPEUTICS INC: AGREEMENT ALSO INCLUDES DEVELOPMENT
AND
REGULATORY MILESTONES UP TO USD 40 MILLION
    * COYA THERAPEUTICS: ELIGIBLE TO GET SALES-BASED MILESTONE
PAYMENTS OF UP TO USD 677.25 MILLION LINKED TO TIERS OF
CUMULATIVE NET SALES ACHIEVED OVER YEARS

Source text for Eikon:  ID:nBw8nGpk0a 
Further company coverage:  COYA.O 

 ((Reuters.Briefs@thomsonreuters.com;))